Breakthrough Alzheimer's drugs too pricey to be offered on NHS
Two breakthrough Alzheimer's drugs have been deemed far too expensive, for too little benefit, to be offered on the NHS.The medicines are the first to slow the disease, which may give people extra time living independently.The National Institute for Health and Care Excellence (NICE) concluded they were a poor use of taxpayers' money and said funding them could lead to other services being cut.Campaigners say it is a disappointment, but dementia experts have also supported the decision.
The two drugs, donanemab and lecanemab, both help the body clear a gungy protein that builds up in the brains of people with Alzheimer's disease.The medicines do not reverse or even stop the disease, rather brain power is lost more slowly with treatment.Clinical trials of these drugs were celebrated as a scientific triumph as they showed, for the first time, it was possible to change the course of Alzheimer's.But since then a row has developed over the cost of the drugs and how meaningful the benefit is.
The official price in the US is £20,000-£25,000 per patient per year. What the NHS would pay is confidential.Around 70,000 people in England with mild dementia would have been eligible, potentially putting the bill in the region of £1.5bn a year for the drugs alone.NHS resources, including regularly infusing the drugs directly into spinal fluid and frequent brain scans to manage dangerous side effects, would also massively ramp up the cost.
The benefit of the drugs is also debated. They potentially delay the transition from mild to moderate dementia by four-to-six months. That could mean more time without needing daily care, driving, being present for significant family events and socialising.But Prof Rob Howard, from University College London, said real-world benefits "were too small to be noticeable". In trials of lecanemab, patients were better off by 0.45 points, on an 18-point scale ranging from healthy to severe dementia.Yet he said the cost would "have been close to the cost of a nurse's salary for each treated patient".The decision not to fund the drugs is not a surprise. The first assessment last year concluded they were not cost-effective.Helen Knight, director of medicines evaluation at NICE, acknowledged the latest news would be "disappointing" but said the benefits were "modest" at best while requiring "substantial resources"."If they were approved they could displace other essential treatments and services that deliver significant benefits to patients," she said.
NICE said its appraisal had factored in potential savings in the cost of providing care, but the drugs were still deemed unaffordable.NICE decisions apply to the NHS in England, but are normally adopted by Wales and Northern Ireland too. Scotland has its own method for approving drugs.The pharmaceutical companies have three weeks to raise concerns about how the review was performed, otherwise the decision becomes final on 23 July.Both pharmaceutical companies involved, Eisai for lecanemab and Eli Lilly for donanemab, say they will appeal against the decision. Nick Burgin, from Eisai said the NHS "is not ready" for the challenge of tackling Alzheimer's and flaws in the process meant their drug would have been rejected "even if Eisai provided lecanemab to the NHS for free".Eli Lilly, the company behind donanemab, has already expressed its disappointment. "If the system can't deliver scientific firsts to NHS patients, it is broken," said Chris Stokes, Eli Lilly's president and general manager of UK and Northern Europe.
Is this a distraction or a disappointment?
The sentiment was echoed by both the Alzheimer's charities. Prof Fiona Carragher, from the Alzheimer's Society said "the science is flying but the system is failing" and it was "highly disappointing" the drugs were not available on the NHS.Hilary Evans-Newton, the chief executive at Alzheimer's Research UK, said the result was "painful" and patients will miss out on this and future innovations "not because science is failing, but because the system is".However, others say NICE has made the right call. Tom Dening, professor of dementia research at the University of Nottingham, said he was "in complete support" as the benefits of the drugs were "minimal" and a "distraction" from the real issues in dementia."[Namely the] unglamorous challenge of providing people with dementia and their families with activities, care and support that we already know are beneficial for their mental and physical health," he said.Prof Atticus Hainsworth, from St George's, University of London, said: "NICE is simply doing its job."Beyond lecanemab and donenamab there are 138 dementia medicines being tested in 182 trials around the world.Prof Tara Spires-Jones, director of the centre for discovery brain sciences at the University of Edinburgh, said: "There is hope for safer, more effective treatments on the horizon."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BBC News
31 minutes ago
- BBC News
Why your hayfever may be bad at the moment
Sneezing, itchy and running eyes, or a scratchy throat. All can take the pleasure out of a sunny summers day, and all could be due to pollen levels in your the next few days very high grass pollen levels are predicted across the respite should come for some from Sunday onwards as we move to slightly breezier, more changeable you're not on your own as pollen-induced hayfever affects approximately 13 million people in the UK and around 95% of those cases can be attributed to grass. We are currently just past the peak of the grass pollen season, which generally runs from late May to early we can expect regional variations in the length and potency of that across the northern Scotland it tends to be shorter, but in areas such as south-east England grass pollen can continue to affect some people all the way through until early not just grass pollen that could be the cause of those sneezes at the moment pollen and fungal spores are also on the rise as they head towards their summer peak. Whilst dry and warm weather are often responsible too, some types of fungal spores, such as Leptosphaeria can increase temporarily during you're very badly affected at the moment you might be pleased to know that this year grass pollen levels aren't expected to be above average over all. Met Office spokesperson Stephen Dixon said this is due to the UK weather in late spring where the combination of warm weather increased grass growth, but the dry conditions conversely reduced that growing potential."While short dry spells and high temperatures mid-season can increase pollen levels, over a prolonged period this could lead to depletion of the available pollen on the plants," he added. When are pollen levels at their highest? Pollen levels can vary from day to day, even hour to hour depending on weather are at their highest during dry and in warm weather, but can decline if the dry spell is a prolonged onset of rainfall helps to dampen down pollen, but the return of a dry and sunny spell can see a sudden rise in levels of day can be crucial too. Hayfever can be at it's worst early morning and from late afternoon onwards. On sunny days, these are the times when winds tend to be at their lightest and the pollen is concentrated in the lower atmosphere, close to nose and eyes. Is there anything I can do to avoid pollen? It's not an easy thing to avoid here in the UK.A first step could be to check the forecast where you are. Up to date forecasts are available on the BBC Weather website and app from late spring to early search for your location and you will find the latest data alongside the UV forecast. If you are particularly susceptible to hayfever try to avoid being outdoors early and in late in the day when pollen levels can be at their and changing your clothes once you've returned home can help to reduce the be mindful when hanging washing out on high pollen days. Pollen landing on clothes and sheets can then be easily brought don't forget our beloved pets. Limit contact or wash hands after handling them if they have also been you want to escape high pollen days sometimes a trip to the coast may help. However, you will need a location where there is a steady wind coming in off the sea and not the land. Is climate change affecting the pollen season? Like much of the natural world, our changing climate is likely to impact pollen levels in the UK in the years to a Government report on the health affects of climate change in the UK, external there are three ways a warming world could impact pollen patternsChanges in temperature and rainfall patterns could lengthen the pollen season and increase pollen is possible that pollen particles could become more potent, with greater amounts of the allergy causing agent on them.A changing distribution of allergenic plants across the UK, including invasive species, could see potential pollen levels increase in some areas.
The Guardian
36 minutes ago
- The Guardian
Moment historic vote on legalising assisted dying in England and Wales passes
Assisted dying is set to become law after a historic vote in parliament, as MPs passed Kim Leadbeater's bill by 314 to 291 votes, a majority of 23, to legalise the procedure for terminally ill people. Keir Starmer backed the bill which will now head to the House of Lords, though peers are not expected to block its progress. It will give those with less than six months to live in England and Wales the right to an assisted death, after approval from two doctors and a panel including a psychiatrist, social worker and senior lawyer
The Independent
37 minutes ago
- The Independent
Historic vote brings assisted dying closer to becoming law in England and Wales
Assisted dying is a step closer to being made legal in England and Wales after the proposed legislation cleared the House of Commons in a historic vote – albeit with a narrower majority. More than 300 MPs backed a Bill that would allow terminally ill adults with a life expectancy of less than six months to end their lives. Yes campaigners wept, jumped and hugged each other outside parliament as the vote result was announced, while some MPs appeared visibly emotional as they left the chamber. Others lined up to shake hands with Kim Leadbeater, the Bill's sponsor through the Commons, with some, including Home Office minister Jess Phillips, stopping to hug the Spen Valley MP. Despite warnings from opponents around the safety of a Bill they argued has been rushed through, the proposed legislation has taken another step in the parliamentary process. MPs voted 314 to 291, majority 23, to approve Ms Leadbeater's Terminally Ill Adults (End of Life) Bill at third reading. This means the Bill has completed its first stages in the Commons and will move to the House of Lords for further debate and scrutiny. Both Houses must agree the final text of the Bill before it can be signed into law. Due to the four-year implementation period, it could be 2029 – potentially coinciding with the end of this Government's Parliament – before assisted dying is offered. Encouraging or assisting suicide is currently against the law in England and Wales, with a maximum jail sentence of 14 years. Supporters of assisted dying have described the current law as not being fit for purpose, with desperate terminally ill people feeling the need to end their lives in secret or go abroad to Dignitas alone, for fear loved ones will be prosecuted for helping them. Prime Minister Sir Keir Starmer remained supportive of the Bill, voting yes on Friday as he had done last year. Conservative leader Kemi Badenoch, who had urged MPs to vote against the legislation, describing it as 'a bad Bill' despite being 'previously supportive of assisted suicide', voted no. Friday was the first time the Bill was debated and voted on in its entirety since last year's historic yes vote, when MPs supported the principle of assisted dying for England and Wales by a majority of 55 at second reading. Labour MP Ms Leadbeater has argued her Bill will 'correct the profound injustices of the status quo and to offer a compassionate and safe choice to terminally ill people who want to make it'. During an hours-long date on Friday, MPs on both sides of the issue recalled personal stories of loved ones who had died. Conservative former minister Sir James Cleverly, who led the opposition to the Bill in the Commons, spoke of a close friend who died 'painfully' from cancer. He said he comes at the divisive issue 'not from a position of faith nor from a position of ignorance', and was driven in his opposition by 'concerns about the practicalities' of the Bill. MPs had a free vote on the Bill, meaning they decided according to their conscience rather than along party lines. The proposed legislation would allow terminally ill adults in England and Wales, with fewer than six months to live, to apply for an assisted death, subject to approval by two doctors and a panel featuring a social worker, senior legal figure and psychiatrist. Public support for a change in the law remains high, according to a YouGov poll published on the eve of the vote. The survey of 2,003 adults in Great Britain, suggested 73% of those asked last month were supportive of the Bill, while the proportion of people who feel assisted dying should be legal in principle stood at 75%.
